Reducing the cost of screening novel agents using the hollow fibre assay

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 2049-2052

  Shnyder, S D ^a   Cooper, P A ^a   Scally, A J ^a   Bibby, M C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Drug evaluation; Hollow fibres; Preclinical

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SCREENING; CELL GROWTH; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HOLLOW FIBER; HOLLOW FIBER ASSAY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOASSAY; IMMUNOCOMPETENCE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LUNG NEOPLASMS; MICE; MICE, NUDE; PACLITAXEL;

EID: 33745590697     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L and Grever MR: In vivo cultivation of tumor cells in hollow fibers. Life Sci 57: 131-141, 1995.
2. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M and Sausville EA: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431, 2001.
3. Decker S, Hollingshead M, Bonomi CA, Carter JP and Sausville EA: The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer 40: 821-826, 2004.
4. Chu MY, Lipsky MH, Yee LK, Epstein J, Whartenby KA, Freeman S, Chen TM, Chu E, Forman EN and Calabresi P: Predictive sensitivity of human cancer cells in vivo using semipermeable polysulfone fibers. Pharmacology 56: 318-326, 1998.
5. Friberg LE, Hassan SB, Lindhagen E, Larsson R and Karlsson MO: Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. Eur J Pharm Sci 25: 163-173, 2005.
6. Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K and Larsson R: Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemother Pharmacol 46: 493-500, 2000.
7. Leong CO, Suggitt M, Swaine DJ, Bibby MC, Stevens MF and Bradshaw TD: In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Ther 3: 1565-1575, 2004.
8. Suggitt M, Swaine DJ, Pettit GR and Bibby MC: Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo. Clin Cancer Res 10: 6677-6685, 2004.
9. Lanza RP, Butler DH, Borland KM, Staruk JE, Faustman DL, Solomon BA, Muller TE, Rupp RG, Maki T, Monaco AP and Chick WL: Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression. Proc Natl Acad Sci USA 88: 11100-11104, 1991.
10. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T and Wallace J: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 77: 1-10, 1998.
11. Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC and Bibby MC: Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res 25: 1889-1894, 2005.
12. Bogden AE, Haskell PM, LePage DJ, Kelton DE, Cobb WR and Esber HJ: Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol 47: 281-293, 1979.
13. Aamdal S, Fodstad O and Pihl A: Human tumor xenografts transplanted under the renal capsule of conventional mice. Growth rates and host immune response. Int J Cancer 34: 725-730, 1984.
14. Bogden AE, Cobb WR, Lepage DJ, Haskell PM, Gulkin TA, Ward A, Kelton DE and Esber HJ: Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay. Cancer 48: 10-20, 1981.
15. Toffoli G, Tumiotto L, Gigante M, Dall'Arche MG, Perin T and Boiocchi M: Increased chemosensitivity to doxorubicin of intrinsically multidrug-resistant human colon carcinoma cells by prolonged exposure to verapamil. Eur J Cancer 29A: 1776-1778, 1993.